Cytheris Announces Initiation of NIAID/NIH-Sponsored Phase I/IIa Clinical Trial of Interleukin-7 (IL-7)
News Oct 14, 2009
Cytheris SA, a clinical stage biopharmaceutical company focused on the research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL). ICL is a rare, orphan disease characterized by abnormally low CD4 T cell counts without evidence of human immunodeficiency virus (HIV-1 or HIV-2) infection. The trial is a further investigation of Cytheris' promising investigative immunotherapy, CYT107 (recombinant human interlukin-7, or IL-7), already the subject of six other studies for different indications.
The study is sponsored, conducted and partially funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). Under the direction of Irini Sereti, M.D., M.H.S., NIAID/NIH Study Investigator, the trial is designed to assess the safety and biological effects of repeated administration of CYT107 and will be conducted at the NIH Clinical Center in Bethesda, Maryland, the largest US hospital devoted entirely to clinical research.
"Since its inception in 1999, Cytheris has had a close relationship with IL-7 investigators at the US National Institutes of Health, a connection that has played a pivotal role in bringing the potential of this cytokine to the attention of the medical community," said Michel Morre, DVM, President and CEO of Cytheris. "We are very pleased that NIH has again recognized the value of the IL-7 program and has chosen to provide financial support as well as the participation of NIAID investigators in this clinical development program focused on ICL."
The trial is called ICICLE (Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells). It is a Phase I/IIa open-label, single arm clinical trial evaluating the safety profile of glycosylated recombinant human interleukin-7 (rhIL-7) as an immune modulator in patients with ICL at risk of disease progression. Secondary analyses will assess the immunostimulatory effects of rhIL-7 on T cell numbers and function.
"ICL patients have a propensity to develop serious co-morbidities and the dearth of treatment options for their primary lymphocytopenia, particularly in patients who have experienced opportunistic or otherwise serious infections, means that the unmet medical need to establish novel immune treatments for ICL patients persists," said Thérèse Croughs, MD, Chief Medical Officer of Cytheris. "IL-7 represents a promising investigative therapy which has shown in pre-clinical and Phase I studies in oncology and in HIV-infected patients to be well tolerated in repeated dose trials, with long-lasting increases in both CD4 and CD8 T cells."
Study Design and Objectives
This is a single center, open-label, single-arm, Phase I/IIa interventional clinical trial. The study population is defined as men and women, aged >18 years, with a confirmed diagnosis of ICL (CD4 <300 cells/ºL or <20 percent of lymphocytes on two occasions) deemed at risk for complications due to concurrent CD8 T cell lymphocytopenia and/or a history of opportunistic or otherwise serious infection, without autoimmunity or hematologic or lymphoid malignancy.
Participants will be evaluated at baseline (prior to study treatment) and according to the protocol follow-up schedule, receive a total of 2 cycles of subcutaneous rhIL-7 (CYT107) dosed once weekly for 3 weeks in a dose escalation fashion: 3 ºg/kg (first 5 volunteers), 10 ºg/kg (next 5 volunteers) and 20 ºg/kg (last 5 volunteers), with an additional 5 study participants at the highest achieved dose level. Cycles of rhIL-7 will be administered starting at Week 1 and Week 24.
Approximately 35-40 patients will be screened over a 3-year period to achieve the desired sample of 20 ICL patients. Safety assessments of rhIL-7 will be the primary focus at each study visit, with secondary analyses of immune parameters, including changes from baseline in T cell numbers and function, at Weeks 24 and 48. Enrollment is expected to take 3 to 4 years. Each volunteer will be followed for 48 weeks. Thus, total duration of the study will be approximately 5 years.
The exploratory objectives of this study are to evaluate the immunomodulatory effects of rhIL-7:
* Evaluate changes in CD4 and CD8 T cell counts
* Evaluate whether any observed changes in CD4 and CD8 T cell counts are due to increasing thymic output and/or peripheral T cell expansion
* Evaluate effects on T cell activation status
* Evaluate effects on the function and proliferation of antigen-specific T cells
* Evaluate effects on gastrointestinal mucosal lymphocytes
* Evaluate effects on lymph node-based tissue lymphocytes
* Evaluate predictors of response (i.e., increases in CD4 T cells), such as age, baseline total and naïve CD4 T cell counts, baseline CD127 expression on T cells, and MHC haplotype
The restorative effects of exogenous IL-7 on the immune system of ICL patients will be assessed by both flow cytometric immunophenotyping and lymphocyte functional assays to assess the following:
* CD4 and CD8 T cell counts
* Naïve and memory T cell subsets
* Naïve T cells representing recent thymic emigrants
* Activated and proliferating T cells
* T cell apoptosis and survival
* T cell receptor (TCR) repertoire
Additional information on the ICICLE study can be found at clinicaltrials.gov.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Microbiotica Enters into Microbiome Collaboration with GenentechNews
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline.READ MORE